Cellectis S.A. develops gene-edited cell and gene therapies as a clinical-stage biotechnology company. Its recurring news centers on allogeneic CAR T immunotherapies in oncology, including off-the-shelf, gene-edited CAR T-cell product candidates, and on broader gene therapy research using its gene-editing platform and in-house manufacturing capabilities.
Company updates commonly cover clinical and partner-program developments for candidates such as lasme-cel, eti-cel and cema-cel; TALE-based and epigenetic editing research; financial results and business updates; collaborations and license arrangements; and monthly disclosures of share capital and voting rights for its Euronext Growth listing alongside its Nasdaq-listed ADS trading under CLLS.
Cellectis reported as of October 31, 2022, a total of 45,567,810 shares in its capital and 51,634,701 voting rights. This biotechnology company specializes in gene-editing and focuses on developing CAR-T immunotherapies for various cancers. Cellectis employs its proprietary TALEN® technology and PulseAgile system to advance treatments for acute myeloid leukemia and other serious conditions. The company continues to expand its portfolio while maintaining a commitment to address unmet medical needs.
Cellectis reported its Q3 2022 results, highlighting a cash position of $103 million as of September 30, 2022. Revenues fell to $9 million, down from $53 million in the same period last year, primarily due to decreased milestone payments. R&D expenses were $85 million, reflecting notable cost management. The net loss attributable to shareholders decreased to $79 million or $1.74 per share, compared to $89 million in the prior year. Additionally, several clinical trials progressed, including UCART123's upcoming oral presentation at the ASH 2022 Annual Meeting.
Cellectis has announced two abstracts accepted for presentation at the 64th ASH Annual Meeting from December 10-13, 2022. The AMELI-01 study evaluating UCART123 in patients with relapsed/refractory acute myeloid leukemia (r/r AML) will showcase preliminary data, highlighting improved activity with alemtuzumab. Additionally, a poster on UCARTCS1 will present preclinical data demonstrating anti-tumor activity in multiple myeloma. Cellectis aims to address unmet medical needs using its gene-editing platform to develop innovative therapies.
Cellectis, a clinical-stage biotechnology company, is set to announce its Q3 2022 financial results on November 3, 2022, after the US market closes. This will be followed by a conference call on November 4, 2022, at 8:00 AM EDT to discuss the results and provide a business update. Cellectis focuses on developing innovative gene-editing therapies using TALEN® technology and is pioneering off-the-shelf CAR-T immunotherapies. The company is listed on Nasdaq under the symbol CLLS.
Summary not available.
Cellectis, a clinical-stage biotechnology company, announced pre-clinical data on TALEN®-edited CAR T-cells aimed at solid tumors, to be presented at the Society for Immunotherapy of Cancer's 37th Annual Meeting from November 8-12, 2022. Key presentations include:
- Poster on MUC1-targeting CAR T-cells for triple-negative breast cancer (Poster Number: 217).
- Poster on engineering strategies to enhance CAR T-cell efficacy (Poster Number: 325).
Cellectis utilizes its TALEN® technology to develop innovative therapies for unmet medical needs in oncology.
Cellectis, a clinical-stage biotechnology company focused on gene-editing technology, has appointed Dr. Mark Frattini as Chief Medical Officer, effective immediately. Dr. Frattini has over 20 years of experience in hematological malignancies and was previously Senior Vice President of Clinical Sciences at Cellectis. His role will encompass overseeing clinical research and development for the company's UCART clinical trial programs. Dr. Frattini's extensive expertise aims to advance the company’s CAR T-cell therapies, addressing critical patient needs in blood cancer treatment.
Cellectis, a clinical-stage biotechnology company, is advancing its gene-editing technology, TALEN®, to develop innovative cell therapies for cancer treatment. As of August 31, 2022, the company reported a total of 45,550,810 shares in capital and 51,615,672 voting rights. With over 22 years of expertise in gene editing, Cellectis focuses on off-the-shelf CAR-T therapies aimed at various blood cancers, including AML and B-ALL. The company is listed on both the Nasdaq Global Market (ticker: CLLS) and Euronext Growth (ticker: ALCLS).
Cellectis, a clinical-stage biotechnology company focused on gene editing, has announced its participation in four upcoming investor conferences. These events include Citi's 17th Annual Biopharma Conference on September 7, 2022, and the Wells Fargo 2022 Healthcare Conference from September 7-9, followed by presentations at the Baird Global Healthcare Conference on September 13 and the Jefferies Cell and Genetic Medicine Summit on September 29. Cellectis is dedicated to developing innovative therapies for cancer and genetic diseases using its proprietary TALEN® technology and aims to provide treatment options for various cancers.
Cellectis announced its share and voting rights update as of July 31, 2022. The total number of ordinary shares in circulation stands at 45,510,810, with total voting rights reaching 51,875,672. This report is part of compliance with the French financial markets authority regulations.
As a leading clinical-stage biotechnology company, Cellectis is focused on developing innovative cell and gene therapies utilizing its gene-editing technology, TALEN®, and aims to address unmet medical needs in oncology.